Search results for "Initial treatment"

showing 8 items of 8 documents

Outcome of Patients With Differentiated Thyroid Cancer Treated With 131-Iodine on the Basis of a Detectable Serum Thyroglobulin Level After Initial T…

2019

Background: In patients with differentiated thyroid cancer (DTC) and raising serum thyroglobulin (Tg) after total or near-total thyroidectomy and 131I remnant ablation an empiric 131I therapy may be considered. However, outcome data after empiric therapy in did not show a clear evidence of improved survival. We assessed the efficacy of such empiric 131I therapy in patients with DTC and evaluated the long-term outcome.Methods: A total of 100 patients with DTC showing raised Tg level during follow-up after thyroidectomy and 131I ablation were treated with a further 131I therapy (6.1 ± 1.7 GBq). Whole-body scan (WBS) was performed 5–7 days after therapy. Tg value at 12 months after 131I therap…

0301 basic medicinewhole body scanmedicine.medical_specialtymedicine.medical_treatmentEndocrinology Diabetes and Metabolismchemistry.chemical_element030209 endocrinology & metabolismIodinethyroglobulinlcsh:Diseases of the endocrine glands. Clinical endocrinologyGastroenterology03 medical and health sciences0302 clinical medicineStable DiseaseEndocrinologyInternal medicinemedicineInitial treatmentProgression-free survivalThyroid cancerdifferentiated thyroid carcinomaOriginal Researchlcsh:RC648-665business.industry131I empiric therapyThyroidectomymedicine.disease030104 developmental biologychemistryThyroglobulinprognosisbusinessdifferentiated thyroid carcinoma 131I empiric therapy prognosis thyroglobulin whole body scanEmpiric therapyFrontiers in endocrinology
researchProduct

Argentum-quarz solution in the treatment of anorectal fistulas: Is it possible a conservative approach?

2012

Patients suffering from chronic intestinal diseases (Crohn's disease, Ulcerative Colitis, Indeterminate Colitis) are prone to the development of pyogenic complications. These complications are most commonly in the form of perianal or intraabdominal abscesses and/or fistulas. The treatment of these complications are managed differently but, after an initial treatment based on medical or minimally invasive management, the solution of the pathological condition is always achieved by a surgical procedure. In the last few years prospective studies have proposed an alternative conservative therapeutic approach based on application of fibrin glue in the healing of patients with fistulas-in-ano. In…

Intestinal bowel diseasemedicine.medical_specialtySilverDiseaseFibrin Tissue AdhesiveModels BiologicalTherapeutic approachmedicineInitial treatmentHumansRectal FistulaProspective cohort studyFibrin gluePathologicalCell ProliferationAnorectal FistulaWound Healingbusiness.industryCell DifferentiationChronic inflammationGeneral MedicineQuartzFibroblastsmedicine.diseaseUlcerative colitisSurgerySolutionsSettore MED/18 - Chirurgia GeneraleAnorectal fustulabusinessIntestinal bowel diseases; Anorectal fustulas; Chronic inflammation
researchProduct

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry

2019

Background: Bypassing agents are the first line therapy in patients with acquired haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be effective as initial treatment, but 20% of patients (pts) had relapses. aPCC as short-term prophylaxis to reduce subsequent bleeds is still not clear. Aim: To evaluate whether a short-term prophylaxis with low dose of aPCC can reduce bleeding relapses after initial AHA treatment, maintaining safety. Methods: The FAIR Registry is a retrospective-prospective study started on December 2012, that collected data on all pts with AHA treated with aPCC in 12 Italian Haemophilia Centers. All statistical analyses were carried out in the 5…

Malemedicine.medical_specialtyAcquired haemophilia; Bleeding relapses; Bypassing agents; Prophylaxis; Aged; Female; Hemophilia A; Hemorrhage; Humans; Male; Prospective Studies; Recombinant Proteins; Recurrence; Retrospective StudiesHemorrhage030204 cardiovascular system & hematologyHemophilia AHaemophilia03 medical and health sciences0302 clinical medicineFirst line therapyRecurrenceInternal medicineAcquired haemophiliamedicineHumansInitial treatmentIn patientProspective StudiesProphylaxiActivated prothrombin complex concentrateBypassing agentAgedRetrospective StudiesHematologyProphylaxisbusiness.industryLow doseBleeding relapseHematologymedicine.diseaseRecombinant Proteins030220 oncology & carcinogenesisFemaleBleeding relapsesBypassing agentsbusinessAcquired haemophiliaThrombosis Research
researchProduct

Temporomandibular chronic dislocation : the long-standing condition

2016

Background The temporomandibular joint (TMJ) dislocation can be categorised into three groups: acute, habitual or recurrent and long-standing. The long-standing or protracted lower jaw dislocation refers to a condition that persists for more than one month without reduction. There are a great variety of methods for its treatment, from the manual or non-surgical, to surgical ones like the indirect approach (conservative surgical approach) and direct approach (open joint). Additional procedures in unsuccessful cases may include extra-articular orthognathic techniques to correct a malocclusion until joint replacement. Material and Methods We report four new cases with a minimum of 6 weeks disl…

Malemedicine.medical_specialtyJoint replacementmedicine.medical_treatmentJoint DislocationsReview03 medical and health sciences0302 clinical medicineDislocation (syntax)medicineHumansInitial treatmentJoint dislocation030223 otorhinolaryngologyGeneral DentistryReduction (orthopedic surgery)Orthodonticsbusiness.industryOpen surgery030206 dentistryMiddle AgedTemporomandibular Joint Disordersmedicine.disease:CIENCIAS MÉDICAS [UNESCO]SurgeryTemporomandibular jointOrofacial Pain-TMJDmedicine.anatomical_structureJawOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASFemaleSurgeryMalocclusionbusinessMalocclusion
researchProduct

Multicentric recurrent parotid pleomorphic adenoma in a child

2009

Mixed tumours of the parotid gland are rare in childhood and recurrence of this tumour is infrequent. Some authors report a higher rate of recurrence with some histological subtypes, like hypocellular variant. Female sex and young age at initial treatment are also risk factor for recurrence. Also the first surgical treatment, tumour enucleation or parotidectomy, has been implicated as a cause for recurrence. We present a case of a multicentric doubly recurrent parotid pleomorphic adenoma, 7 and 14 years after tumour enucleation, in a 9-year-old child. All the nodules resected showed the hypocellular variant of pleomorphic adenoma. We consider the relationships between the choice of treatmen…

Pathologymedicine.medical_specialtyAdolescentEnucleationAdenoma PleomorphicPleomorphic adenomamedicineHumansInitial treatmentRisk factorChildGeneral Dentistrybusiness.industryParotidectomy:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseParotid NeoplasmsParotid glandstomatognathic diseasesYoung agemedicine.anatomical_structureParotid Pleomorphic AdenomaOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASFemaleSurgeryNeoplasm Recurrence LocalbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

2010

The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabe…

cardiovascular riskGlucose-lowering therapyEndocrinology Diabetes and MetabolismeducationSocieties Medical/standardsMEDLINE10265 Clinic for Endocrinology and DiabetologyHypoglycemic Agents/therapeutic use610 Medicine & healthType 2 diabetesHyperglycemia/drug therapyLifestyle modificationRisk FactorsDiabetes mellitusTier 2 networkADA Consensus StatementmedicineInternal MedicineInitial treatmentHyperglycaemiaHumansIn patientFor Debatealgorithmbusiness.industrynutritional and metabolic diseasesType 2 diabetesmedicine.diseaseCardiovascular riskUnited StatesMetforminEASD consensus statementglucose-lowering therapyAlgorithmEurope2712 Endocrinology Diabetes and Metabolism2724 Internal Medicine*AlgorithmsDiabetes Mellitus Type 2/complications/*drug therapytype 2 diabetesbusinessAlgorithmCardiovascular Diseases/prevention & controlhyperglycaemiamedicine.drug
researchProduct

A survey on current practice in the neurosurgical management of preterm infants with posthemorrhagic hydrocephalus in Germany.

2012

Background and Study Aims  Different approaches to the management of preterm infants with posthemorrhagic hydrocephalus (PHH) are described in the literature. Likewise, neurosurgical and pediatric surgical departments in German hospitals use different methods to treat these patients. The aim of this study was therefore to assess the current situation regarding the management of PHH, which is a first and essential step toward the development of standards of practice. Patients and Methods  In the second half of 2009, we sent standardized questionnaires to 139 neurosurgical departments (number of returned questionnaires: 98) and 73 pediatric surgical departments (returned questionnaires: 62) t…

medicine.medical_specialtyPediatricsNeurosurgeryPediatricsVentriculoperitoneal ShuntNeurosurgical ProceduresVentriculoperitoneal shuntsPosthemorrhagic hydrocephalusGermanySurveys and QuestionnairesPediatric surgeryMedicineInitial treatmentHumansPractice Patterns Physicians'Csf shuntbusiness.industryData CollectionInfant Newbornmedicine.diseasehumanitiesIntraventricular hemorrhageCurrent practicePractice Guidelines as TopicSurgeryNeurology (clinical)NeurosurgerybusinessIntracranial HemorrhagesInfant PrematureHydrocephalusJournal of neurological surgery. Part A, Central European neurosurgery
researchProduct

Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.

2011

Introduction: Pemphigus is an autoimmune blistering disease of the skin and mucous membranes characterized by the development of autoantibodies against the desmosomal proteins, desmoglein-1 and -3. Before the advent of corticosteroids, therapy was almost fatal. The introduction of high-dose corticosteroid therapy has reduced mortality rates to similar to 10%, but long-term use of steroids can lead to side effects, many of which are severe and associated with significant morbidity. Thus, the major goal of pemphigus therapy has been to reduce the patient's cumulative exposure to systemic corticosteroids. Over the last 2 decades, a range of corticosteroid-sparing immunosuppressive agents have …

medicine.medical_specialtyToxicologyMycophenolateMycophenolic acidPharmacokineticsAdrenal Cortex HormonesmedicineInitial treatmentimmunosuppressant inosine monophosphate dehydrogenase mycophenolate mofetil mycophenolic acid pemphigus pharmacokinetic treatmentHumansPharmacologyintegumentary systembusiness.industryMortality rateAutoantibodyGeneral MedicineMycophenolic Acidmedicine.diseaseDermatologyPemphigusImmunologybusinessImmunosuppressive AgentsPemphigusmedicine.drugBlistering diseaseExpert opinion on drug metabolismtoxicology
researchProduct